Divergence Between MHRA and EMA in Clinical Trial Oversight

Following Brexit, the Medicines and Healthcare products Regulatory Agency (MHRA) assumed full authority over the regulation of clinical trials in the United Kingdom (UK), while the European Medicines Agency (EMA) retained oversight within the European Union (EU). While both agencies share a commitment to Good Clinical Practice (GCP) and international harmonisation, important divergences have emerged. These differences affect clinical trial authorisations, pharmacovigilance obligations, transparency requirements, and inspection practices. Sponsors operating global or multi-regional trials must understand these divergences to remain compliant and to ensure trial data generated in the UK remains globally acceptable.

This article analyses areas where MHRA and EMA oversight aligns, and where post-Brexit divergence has created new obligations for sponsors, investigators, and CROs conducting trials in the UK and EU.

Background and Regulatory Framework

Pre-Brexit Alignment

Before Brexit, the UK followed EU Clinical Trials Directive 2001/20/EC and prepared for the EU Clinical Trials Regulation (CTR) 536/2014. Approvals, safety reporting, and transparency obligations were harmonised under EMA-led structures.

Post-Brexit Separation

From January 2021, UK clinical trial regulation became independent. While MHRA retained alignment with ICH GCP and WHO guidance, the UK introduced standalone guidance and adapted approval pathways for Clinical Trial Authorisations (CTAs).

Global Harmonisation

Both EMA and MHRA continue to align with ICH guidelines, but divergence in implementation details, systems (CTIS vs UK portals), and timelines has created complexity for sponsors managing multinational trials.

Key Areas of Divergence

1. Clinical Trial Authorisation (CTA) Process

The EU requires sponsors to submit applications through the Clinical Trials Information System (CTIS), ensuring single dossier review across Member States. In contrast, the UK requires direct submission to MHRA via its own systems, creating duplication for multinational sponsors.

2. Transparency and Registries

EMA mandates public disclosure of trial documents via CTIS, including protocols and lay summaries. The UK relies on ISRCTN or ClinicalTrials.gov, with HRA enforcing results disclosure within 12 months. This leads to fragmented transparency obligations.

3. Safety Reporting Obligations

Both EMA and MHRA require prompt reporting of SUSARs and DSURs. However, the EU uses EudraVigilance for centralised submissions, while the UK operates a separate MHRA safety reporting portal.

4. Inspections and GCP Enforcement

EMA coordinates GCP inspections across Member States, while MHRA conducts independent inspections in the UK. Reports show that MHRA has focused heavily on data integrity and TMF completeness, while EMA emphasises harmonisation and systemic oversight.

5. Data Protection and GDPR

EU Member States follow GDPR, whereas the UK applies the Data Protection Act 2018 and the Data Protection and Digital Information (DPDI) Bill. While principles remain similar, operational differences can complicate multinational trial data handling.

6. Decentralised and Hybrid Trials

EMA is developing reflection papers on decentralised elements, while MHRA has been quicker to adopt DCT frameworks, allowing home delivery of IMPs and eConsent validation. This divergence may make the UK a more flexible jurisdiction for early adoption of digital models.

Best Practices for Sponsors Managing Divergence

• Plan dual submissions to CTIS (EU) and MHRA portals (UK).
• Maintain separate pharmacovigilance reporting workflows for MHRA and EMA.
• Develop harmonised SOPs to address both GDPR and UK data protection requirements.
• Monitor evolving MHRA guidance, especially around DCTs and inspection priorities.
• Conduct regular TMF audits to align with both EMA and MHRA expectations.

Scientific and Regulatory Evidence

• EU Clinical Trials Regulation 536/2014
• Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended)
• MHRA Guidance on Clinical Trials Post-Brexit
• EMA Reflection Paper on Decentralised Trials
• ICH E6(R2) and draft E6(R3) GCP Guidelines

Special Considerations

• Oncology Trials: Divergent reporting rules may delay multinational oncology programmes unless harmonised SOPs are in place.
• Rare Diseases: UK flexibility for decentralised models may provide better access for geographically dispersed patients.
• Pediatrics: Divergence in REC expectations requires dual adaptation of consent and assent materials.
• Advanced Therapies: EMA and MHRA differ in inspection focus for ATMPs, with MHRA placing more weight on long-term follow-up documentation.

When Sponsors Should Seek Regulatory Advice

• When planning multinational trials involving both UK and EU sites.
• For rare disease or paediatric studies requiring harmonised submissions.
• If trial designs involve decentralised elements subject to divergent regulatory acceptance.
• For guidance on managing parallel PV and data protection requirements.
• When preparing global submissions relying on both EMA and MHRA trial data.

FAQs

1. How do CTA processes differ between MHRA and EMA?

EMA uses CTIS for centralised submissions across EU Member States, while MHRA requires separate national submissions.

2. Are transparency obligations different in the UK and EU?

Yes. EMA mandates disclosure in CTIS, while the UK relies on ISRCTN and HRA timelines.

3. How does safety reporting differ?

EMA uses EudraVigilance, while MHRA has its own reporting systems, requiring sponsors to maintain dual workflows.

4. Does GDPR apply to UK trials?

The UK applies the Data Protection Act 2018 and DPDI Bill. GDPR no longer applies directly, but principles remain similar.

5. Which agency is more flexible with DCTs?

MHRA has shown greater flexibility, permitting home IMP delivery and eConsent validation sooner than EMA.

6. Do MHRA inspections differ from EMA inspections?

Yes. MHRA inspections focus strongly on TMF completeness and data integrity, while EMA coordinates systemic oversight across Member States.

7. What are the implications for global sponsors?

Global sponsors must manage dual systems, reporting obligations, and regulatory expectations to avoid delays and findings.

Conclusion

The divergence between MHRA and EMA in clinical trial oversight reflects the broader regulatory separation post-Brexit. While both agencies remain committed to GCP and international harmonisation, sponsors must adapt to differences in CTA processes, transparency obligations, pharmacovigilance systems, and inspection priorities. A proactive approach—engaging with regulators, aligning SOPs, and leveraging CRO expertise—will ensure trials in both regions remain compliant, efficient, and globally credible.

Assessing Brexit’s Impact on EU Clinical Trial Regulation and Operations

The departure of the United Kingdom (UK) from the European Union (EU) marked a turning point for pharmaceutical research and regulatory frameworks across Europe. Prior to Brexit, the UK played a central role in shaping EU clinical trial regulations, hosting many pivotal trials, and serving as a key contributor to the European Medicines Agency (EMA). Since Brexit, EU trial regulation has continued under CTR 536/2014 with harmonized processes via the Clinical Trials Information System (CTIS), while the UK has adopted its own regulatory framework under the Medicines and Healthcare products Regulatory Agency (MHRA). This divergence has significant implications for sponsors, CROs, and investigators conducting cross-border clinical trials.

This article explores how Brexit has influenced EU clinical trial regulation, highlighting operational, regulatory, and scientific challenges while offering best practices for navigating this dual system.

Background and Regulatory Framework

The UK’s Role Pre-Brexit

Before Brexit, the UK was one of the most active clinical research hubs in Europe. The MHRA and UK research institutions were instrumental in shaping EU GCP guidelines, ethical frameworks, and policy innovations, including early adoption of adaptive trial designs.

Post-Brexit Divergence

Since January 1, 2021, the UK no longer falls under EU CTR 536/2014. Instead, it regulates clinical trials independently via MHRA guidance and UK-specific legislation. Although the UK has aligned many processes with ICH E6(R2) and ICH E8(R1), key divergences exist in timelines, submissions, and safety reporting obligations.

Core Clinical Trial Insights: Brexit’s Impact

1. Clinical Trial Applications and Submissions

EU trials now require submission via CTIS, while UK trials must be submitted separately through MHRA’s combined review service. Sponsors planning pan-European studies must navigate dual submissions, doubling administrative and resource burdens.

2. Regulatory Timelines

CTR 536/2014 enforces harmonized timelines for Part I and Part II assessments across Member States. In contrast, MHRA timelines differ, with expedited reviews possible for certain high-priority studies, but without the same coordinated multi-country mechanism available in the EU.

3. Ethics Committee Oversight

In the EU, ethics reviews are governed by Member State frameworks integrated into the CTR process. In the UK, the Health Research Authority (HRA) continues to coordinate ethics reviews, which remain separate from EU systems. This creates duplication for sponsors running joint EU-UK trials.

4. Data Protection and GDPR

The EU’s General Data Protection Regulation (GDPR) applies across Member States, while the UK has adopted its own version (“UK GDPR”). While largely equivalent today, future divergence may complicate cross-border data sharing and trial monitoring.

5. Supply Chain Logistics

Brexit introduced customs barriers and import/export complexities for investigational products. Sponsors now require separate Qualified Person (QP) release in both the EU and UK, creating potential delays and added costs in trial supply chains.

6. Pharmacovigilance and Safety Reporting

EU SUSAR reporting is centralized via EudraVigilance. Post-Brexit, the UK requires safety reports to be submitted to the MHRA separately. Sponsors must maintain parallel safety databases and reporting systems for compliance.

7. Research Collaboration and Site Participation

Many pan-European consortia that previously included UK sites must now treat the UK as a third country, requiring additional agreements and approvals. This has reduced UK participation in some EU-funded Horizon Europe projects, although new association agreements are restoring partial access.

8. Impact on Patients and Recruitment

Brexit has affected patient recruitment by creating uncertainty for multinational trials. However, the UK’s streamlined MHRA pathways aim to attract more early-phase and innovative trials, while EU CTR supports large multi-country Phase III studies.

Best Practices & Preventive Measures

• Develop dual regulatory strategies for EU and UK submissions.
• Engage with both EMA and MHRA for early scientific advice.
• Establish separate QP release processes for EU and UK supply chains.
• Maintain harmonized SOPs for pharmacovigilance covering both jurisdictions.
• Leverage local CROs or affiliates for expertise in both regulatory systems.

Scientific and Regulatory Evidence

• EU Clinical Trial Regulation (CTR) 536/2014
• MHRA Clinical Trials Guidance (UK)
• EMA and HMA Brexit Q&A guidance documents
• ICH E6(R2) – Good Clinical Practice
• GDPR (EU) and UK GDPR frameworks

Special Considerations

Brexit’s impact is particularly significant in:

• Advanced Therapies (ATMPs): Dual oversight from EMA CAT and MHRA.
• Rare Diseases: Cross-border recruitment challenges due to small patient populations.
• Decentralized Trials: Diverging acceptance of telemedicine and direct-to-patient models in the EU and UK.
• Oncology: Parallel submissions complicate large-scale Phase III cancer trials.

When Sponsors Should Seek Regulatory Advice

• When planning multi-country studies involving both EU and UK sites.
• If data transfers between EU and UK are critical for trial endpoints.
• Before sourcing IMPs across borders post-Brexit.
• When implementing hybrid or decentralized trial models in both regions.
• For rare disease or ATMP trials requiring dual oversight.

FAQs

1. Does the UK still follow EU CTR 536/2014?

No. The UK is no longer bound by CTR 536/2014 and has adopted MHRA-specific processes for clinical trial regulation.

2. Are EU and UK GCP requirements aligned?

Yes, both jurisdictions align with ICH E6(R2), but operational processes differ significantly.

3. Can a single submission cover both EU and UK trials?

No. Separate submissions are required via CTIS for the EU and MHRA for the UK.

4. How is pharmacovigilance managed post-Brexit?

Safety reports must be submitted to both EudraVigilance (EU) and MHRA (UK). Parallel systems are mandatory.

5. How does Brexit affect Horizon Europe projects?

UK participation was initially reduced but partial association agreements are restoring some collaborative opportunities.

6. Do QP release requirements differ?

Yes. Separate QP release is required in both the EU and UK for IMPs, increasing operational complexity.

7. Which trials are most affected by Brexit?

Multi-country Phase III studies, ATMP trials, and rare disease studies are particularly impacted due to cross-border dependencies.

Conclusion

Brexit has introduced complexity into the clinical trial landscape by creating parallel regulatory systems in the EU and UK. While the EU continues to advance harmonization through CTR 536/2014, the UK is positioning itself as a flexible hub for innovative and early-phase trials. For sponsors, success now depends on developing dual strategies, ensuring compliance with both EMA and MHRA frameworks, and adopting proactive risk management to navigate cross-border challenges. Although Brexit has created barriers, it also presents opportunities for innovation in clinical research if managed effectively.